Articles

E-mail RSS

Rockville, MD - Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and Lentiviral vector manufacturer Lentigen Corp. (Baltimore, MD) today announced signing of a master services agreement for Omnia to provide Lentigen with access to its cGMP facilities and services.

Omnia Biologics (Omnia) is a contract manufacturer focused on clinical trials material manufacture of innovative biopharmaceuticals. Lentigen is a contract manufacturer of research and clinical grade Lentiviral vectors.

Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal: "Combining Dr. Dropulic and his team's leadership and vast experience in Lentiviral vector technology and Omnia's capacity and capabilities to produce cGMP clinical trial materials focused on servicing the needs of novel bio-pharma drug developers, is a great step forward in providing a vital service to the developers of this new and exciting drug platform as well as the patients who will benefit from these advances."

Boro Dropulic, CEO, Lentigen Corporation commented, "We are very pleased to work with Dr. VanderPutten and his highly experienced team at Omnia Biologics. Omnia Biologics is one of several partnerships Lentigen is attracting for development of its Lentiviral vector gene delivery platform technology. Omnia Biologics provides Lentigen manufacturing facilities and expertise for the production of clinical grade Lentiviral vector material."

SOURCE: Omnia Biologics, Inc.